APO Research
Talk to an analyst

APO RESEARCH · REPORT

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs)

Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.

Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.

Selected research

Market Analysis & Forecast

Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Analysis and Forecast 2026-2032

2 January 2026218 pages

Choose your research edition.

Industry ResearchCirculating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Outlook and Growth Opportunities 2026211 pages · $4,250 USDMarket Analysis & ForecastGlobal Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.

Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.

The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.

Read the full market overview

Report Includes

This report presents an overview of global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), also provides the revenue of main regions and countries. Of the upcoming market potential for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) revenue, projected growth trends, production technology, application and end-user industry.

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Segment by Company

Janssen

Qiagen

Advanced Cell Diagnostics

ApoCell

Biofluidica

Clearbridge Biomedics

CytoTrack

Celsee

Fluxion

Gilupi

Cynvenio

On-chip

YZY Bio

BioView

Fluidigm

Ikonisys

AdnaGen

IVDiagnostics

Miltenyi Biotec

ScreenCell

Silicon Biosystems

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Segment by Type

CellSearch

Others

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Segment by Application

Breast Cancer Diagnosis and Treatment

Prostate Cancer Diagnosis and Treatment

Colorectal Cancer Diagnosis and Treatment

Lung Cancer Diagnosis and Treatment

Other Cancers Diagnosis and Treatment

Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CellSearch Major Player Table 3. Others Major Player Table 4. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Breast Cancer Diagnosis and Treatment Major Player Table 6. Prostate Cancer Diagnosis and Treatment Major Player Table 7. Colorectal Cancer Diagnosis and Treatment Major Player Table 8. Lung Cancer Diagnosis and Treatment Major Player Table 9. Other Cancers Diagnosis and Treatment Major Player Table 10. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Trends Table 11. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Drivers Table 12. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Opportunities and Challenges Table 13. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Restraints Table 14. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Region (2021-2026) Table 17. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Region (2027-2032) Table 19. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Players (2021-2026) Table 21. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players Headquarters & Area Served Table 23. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players, Product Type & Application Table 24. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Type (2021-2026) Table 31. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Type (2027-2032) Table 32. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2021-2026) Table 36. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2027-2032) Table 37. Janssen Company Information Table 38. Janssen Business Overview Table 39. Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 41. Janssen Recent Development Table 42. Qiagen Company Information Table 43. Qiagen Business Overview Table 44. Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 46. Qiagen Recent Development Table 47. Advanced Cell Diagnostics Company Information Table 48. Advanced Cell Diagnostics Business Overview Table 49. Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 51. Advanced Cell Diagnostics Recent Development Table 52. ApoCell Company Information Table 53. ApoCell Business Overview Table 54. ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 56. ApoCell Recent Development Table 57. Biofluidica Company Information Table 58. Biofluidica Business Overview Table 59. Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 61. Biofluidica Recent Development Table 62. Clearbridge Biomedics Company Information Table 63. Clearbridge Biomedics Business Overview Table 64. Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 66. Clearbridge Biomedics Recent Development Table 67. CytoTrack Company Information Table 68. CytoTrack Business Overview Table 69. CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 71. CytoTrack Recent Development Table 72. Celsee Company Information Table 73. Celsee Business Overview Table 74. Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 76. Celsee Recent Development Table 77. Fluxion Company Information Table 78. Fluxion Business Overview Table 79. Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 81. Fluxion Recent Development Table 82. Gilupi Company Information Table 83. Gilupi Business Overview Table 84. Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 86. Gilupi Recent Development Table 87. Cynvenio Company Information Table 88. Cynvenio Business Overview Table 89. Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 91. Cynvenio Recent Development Table 92. On-chip Company Information Table 93. On-chip Business Overview Table 94. On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 96. On-chip Recent Development Table 97. YZY Bio Company Information Table 98. YZY Bio Business Overview Table 99. YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 101. YZY Bio Recent Development Table 102. BioView Company Information Table 103. BioView Business Overview Table 104. BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 106. BioView Recent Development Table 107. Fluidigm Company Information Table 108. Fluidigm Business Overview Table 109. Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 111. Fluidigm Recent Development Table 112. Ikonisys Company Information Table 113. Ikonisys Business Overview Table 114. Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 116. Ikonisys Recent Development Table 117. AdnaGen Company Information Table 118. AdnaGen Business Overview Table 119. AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 121. AdnaGen Recent Development Table 122. IVDiagnostics Company Information Table 123. IVDiagnostics Business Overview Table 124. IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 126. IVDiagnostics Recent Development Table 127. Miltenyi Biotec Company Information Table 128. Miltenyi Biotec Business Overview Table 129. Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 131. Miltenyi Biotec Recent Development Table 132. ScreenCell Company Information Table 133. ScreenCell Business Overview Table 134. ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 136. ScreenCell Recent Development Table 137. Silicon Biosystems Company Information Table 138. Silicon Biosystems Business Overview Table 139. Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio Table 141. Silicon Biosystems Recent Development Table 142. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2026) & (US$ Million) Table 143. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2027-2032) & (US$ Million) Table 144. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2026) & (US$ Million) Table 145. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2027-2032) & (US$ Million) Table 146. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021-2026) & (US$ Million) Table 148. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (US$ Million) & (2027-2032) Table 149. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2026) & (US$ Million) Table 150. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2027-2032) & (US$ Million) Table 151. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2026) & (US$ Million) Table 152. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2027-2032) & (US$ Million) Table 153. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021-2026) & (US$ Million) Table 155. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (US$ Million) & (2027-2032) Table 156. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2026) & (US$ Million) Table 157. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2027-2032) & (US$ Million) Table 158. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2026) & (US$ Million) Table 159. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2027-2032) & (US$ Million) Table 160. Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2026) & (US$ Million) Table 161. Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2027-2032) & (US$ Million) Table 162. Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2026) & (US$ Million) Table 163. Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2027-2032) & (US$ Million) Table 164. Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 165. Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Region (US$ Million) & (2021-2026) Table 166. Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Region (US$ Million) & (2027-2032) Table 167. SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2026) & (US$ Million) Table 168. SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2027-2032) & (US$ Million) Table 169. SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2026) & (US$ Million) Table 170. SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2027-2032) & (US$ Million) Table 171. SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 172. SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021-2026) & (US$ Million) Table 173. SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (US$ Million) & (2027-2032) Table 174. Research Programs/Design for This Report Table 175. Authors List of This Report Table 176. Secondary Sources Table 177. Primary Sources List of Figures Figure 1. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Image Figure 2. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Share 2021 VS 2025 VS 2032 Figure 4. CellSearch Image Figure 5. Others Image Figure 6. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Share 2021 VS 2025 VS 2032 Figure 8. Breast Cancer Diagnosis and Treatment Image Figure 9. Prostate Cancer Diagnosis and Treatment Image Figure 10. Colorectal Cancer Diagnosis and Treatment Image Figure 11. Lung Cancer Diagnosis and Treatment Image Figure 12. Other Cancers Diagnosis and Treatment Image Figure 13. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (US$ Million) & (2021-2032) Figure 14. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Type (2021-2032) Figure 21. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2021-2032) Figure 24. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Type (2021-2032) Figure 26. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Application (2021-2032) Figure 27. North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Country (2021-2032) Figure 28. United States Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Type (2021-2032) Figure 33. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Application (2021-2032) Figure 34. Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Country (2021-2032) Figure 35. Germany Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Type (2021-2032) Figure 45. China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Application (2021-2032) Figure 46. Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Type (2021-2032) Figure 48. Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Application (2021-2032) Figure 49. Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Region (2021-2032) Figure 50. Japan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Type (2021-2032) Figure 58. SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Application (2021-2032) Figure 59. SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Country (2021-2032) Figure 60. Brazil Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • CellSearch
  • Others
Applications
  • Breast Cancer Diagnosis and Treatment
  • Prostate Cancer Diagnosis and Treatment
  • Colorectal Cancer Diagnosis and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Other Cancers Diagnosis and Treatment
Companies covered
  • Janssen
  • Qiagen
  • Advanced Cell Diagnostics
  • ApoCell
  • Biofluidica
  • Clearbridge Biomedics
  • CytoTrack
  • Celsee
  • Fluxion
  • Gilupi
  • Cynvenio
  • On-chip
  • YZY Bio
  • BioView
  • Fluidigm
  • Ikonisys
  • AdnaGen
  • IVDiagnostics
  • Miltenyi Biotec
  • ScreenCell
  • Silicon Biosystems

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Type
  3. 1.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CellSearch
  5. 1.2.3 Others
  6. 1.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market by Application
  7. 1.3.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Breast Cancer Diagnosis and Treatment
  9. 1.3.3 Prostate Cancer Diagnosis and Treatment
  10. 1.3.4 Colorectal Cancer Diagnosis and Treatment
  11. 1.3.5 Lung Cancer Diagnosis and Treatment
  12. 1.3.6 Other Cancers Diagnosis and Treatment
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Dynamics
  1. 2.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Trends
  2. 2.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Drivers
  3. 2.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Opportunities and Challenges
  4. 2.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Perspective (2021-2032)
  2. 3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Growth Trends by Region
  3. 3.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2021-2026)
  5. 3.2.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Players
  2. 4.1.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Players (2021-2026)
  3. 4.1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players Headquarters & Area Served
  7. 4.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players, Product Type & Application
  8. 4.5 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market CR5 and HHI
  11. 4.6.3 2025 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Tier 1, Tier 2, and Tier 3
5 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Type
  1. 5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2032)
  3. 5.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Type (2021-2032)
6 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Application
  1. 6.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2032)
  3. 6.3 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Janssen
  2. 7.1.1 Janssen Company Information
  3. 7.1.2 Janssen Business Overview
  4. 7.1.3 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  6. 7.1.5 Janssen Recent Developments
  7. 7.2 Qiagen
  8. 7.2.1 Qiagen Company Information
  9. 7.2.2 Qiagen Business Overview
  10. 7.2.3 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  12. 7.2.5 Qiagen Recent Developments
  13. 7.3 Advanced Cell Diagnostics
  14. 7.3.1 Advanced Cell Diagnostics Company Information
  15. 7.3.2 Advanced Cell Diagnostics Business Overview
  16. 7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  18. 7.3.5 Advanced Cell Diagnostics Recent Developments
  19. 7.4 ApoCell
  20. 7.4.1 ApoCell Company Information
  21. 7.4.2 ApoCell Business Overview
  22. 7.4.3 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  24. 7.4.5 ApoCell Recent Developments
  25. 7.5 Biofluidica
  26. 7.5.1 Biofluidica Company Information
  27. 7.5.2 Biofluidica Business Overview
  28. 7.5.3 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  30. 7.5.5 Biofluidica Recent Developments
  31. 7.6 Clearbridge Biomedics
  32. 7.6.1 Clearbridge Biomedics Company Information
  33. 7.6.2 Clearbridge Biomedics Business Overview
  34. 7.6.3 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  36. 7.6.5 Clearbridge Biomedics Recent Developments
  37. 7.7 CytoTrack
  38. 7.7.1 CytoTrack Company Information
  39. 7.7.2 CytoTrack Business Overview
  40. 7.7.3 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  42. 7.7.5 CytoTrack Recent Developments
  43. 7.8 Celsee
  44. 7.8.1 Celsee Company Information
  45. 7.8.2 Celsee Business Overview
  46. 7.8.3 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  48. 7.8.5 Celsee Recent Developments
  49. 7.9 Fluxion
  50. 7.9.1 Fluxion Company Information
  51. 7.9.2 Fluxion Business Overview
  52. 7.9.3 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  54. 7.9.5 Fluxion Recent Developments
  55. 7.10 Gilupi
  56. 7.10.1 Gilupi Company Information
  57. 7.10.2 Gilupi Business Overview
  58. 7.10.3 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  60. 7.10.5 Gilupi Recent Developments
  61. 7.11 Cynvenio
  62. 7.11.1 Cynvenio Company Information
  63. 7.11.2 Cynvenio Business Overview
  64. 7.11.3 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  66. 7.11.5 Cynvenio Recent Developments
  67. 7.12 On-chip
  68. 7.12.1 On-chip Company Information
  69. 7.12.2 On-chip Business Overview
  70. 7.12.3 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  71. 7.12.4 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  72. 7.12.5 On-chip Recent Developments
  73. 7.13 YZY Bio
  74. 7.13.1 YZY Bio Company Information
  75. 7.13.2 YZY Bio Business Overview
  76. 7.13.3 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  77. 7.13.4 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  78. 7.13.5 YZY Bio Recent Developments
  79. 7.14 BioView
  80. 7.14.1 BioView Company Information
  81. 7.14.2 BioView Business Overview
  82. 7.14.3 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  83. 7.14.4 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  84. 7.14.5 BioView Recent Developments
  85. 7.15 Fluidigm
  86. 7.15.1 Fluidigm Company Information
  87. 7.15.2 Fluidigm Business Overview
  88. 7.15.3 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  90. 7.15.5 Fluidigm Recent Developments
  91. 7.16 Ikonisys
  92. 7.16.1 Ikonisys Company Information
  93. 7.16.2 Ikonisys Business Overview
  94. 7.16.3 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  96. 7.16.5 Ikonisys Recent Developments
  97. 7.17 AdnaGen
  98. 7.17.1 AdnaGen Company Information
  99. 7.17.2 AdnaGen Business Overview
  100. 7.17.3 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  101. 7.17.4 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  102. 7.17.5 AdnaGen Recent Developments
  103. 7.18 IVDiagnostics
  104. 7.18.1 IVDiagnostics Company Information
  105. 7.18.2 IVDiagnostics Business Overview
  106. 7.18.3 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  107. 7.18.4 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  108. 7.18.5 IVDiagnostics Recent Developments
  109. 7.19 Miltenyi Biotec
  110. 7.19.1 Miltenyi Biotec Company Information
  111. 7.19.2 Miltenyi Biotec Business Overview
  112. 7.19.3 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  114. 7.19.5 Miltenyi Biotec Recent Developments
  115. 7.20 ScreenCell
  116. 7.20.1 ScreenCell Company Information
  117. 7.20.2 ScreenCell Business Overview
  118. 7.20.3 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  119. 7.20.4 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  120. 7.20.5 ScreenCell Recent Developments
  121. 7.21 Silicon Biosystems
  122. 7.21.1 Silicon Biosystems Company Information
  123. 7.21.2 Silicon Biosystems Business Overview
  124. 7.21.3 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Portfolio
  126. 7.21.5 Silicon Biosystems Recent Developments
8 North America
  1. 8.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (2021-2032)
  2. 8.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2032)
  3. 8.2.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2026)
  4. 8.2.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2027-2032)
  5. 8.3 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Type (2021-2032)
  6. 8.4 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2032)
  7. 8.4.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2026)
  8. 8.4.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2027-2032)
  9. 8.5 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Application (2021-2032)
  10. 8.6 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country
  11. 8.6.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021-2026)
  13. 8.6.3 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (2021-2032)
  2. 9.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2027-2032)
  5. 9.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2027-2032)
  9. 9.5 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country
  11. 9.6.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (2021-2032)
  2. 10.2 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2032)
  3. 10.2.1 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2026)
  4. 10.2.2 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2027-2032)
  5. 10.3 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Type (2021-2032)
  6. 10.4 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2032)
  7. 10.4.1 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2026)
  8. 10.4.2 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2027-2032)
  9. 10.5 China Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (2021-2032)
  2. 11.2 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2027-2032)
  5. 11.3 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2027-2032)
  9. 11.5 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country
  11. 11.6.1 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue (2021-2032)
  2. 12.2 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country
  11. 12.6.1 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst